KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Change in Acquisitions & Divestments (2016 - 2025)

Historic Change in Acquisitions & Divestments for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $1.3 billion.

  • Vertex Pharmaceuticals' Change in Acquisitions & Divestments rose 1950.91% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 billion, marking a year-over-year increase of 9437.88%. This contributed to the annual value of $4.5 billion for FY2024, which is 43218.93% up from last year.
  • As of Q3 2025, Vertex Pharmaceuticals' Change in Acquisitions & Divestments stood at $1.3 billion, which was up 1950.91% from $1.8 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Change in Acquisitions & Divestments registered a high of $1.8 billion during Q2 2025, and its lowest value of $47.2 million during Q4 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Change in Acquisitions & Divestments averaged around $606.8 million, with its median value being $239.8 million (2023).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Change in Acquisitions & Divestments tumbled by 8135.72% in 2021 and then skyrocketed by 132100.0% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Change in Acquisitions & Divestments (Quarter) stood at $47.2 million in 2021, then skyrocketed by 925.64% to $484.1 million in 2022, then crashed by 54.95% to $218.1 million in 2023, then surged by 569.51% to $1.5 billion in 2024, then dropped by 8.96% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q3 2025, $1.8 billion for Q2 2025, and $1.6 billion during Q1 2025.